Lee J Helman
Overview
Explore the profile of Lee J Helman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
5673
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akshintala S, Sundby R, Bernstein D, Glod J, Kaplan R, Yohe M, et al.
Clin Cancer Res
. 2023 Jul;
29(17):3329-3339.
PMID: 37398992
Purpose: Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The SRC family member YES has been shown...
2.
Flores-Toro J, Jagu S, Armstrong G, Arons D, Aune G, Chanock S, et al.
J Clin Oncol
. 2023 Jun;
41(24):4045-4053.
PMID: 37267580
Data-driven basic, translational, and clinical research has resulted in improved outcomes for children, adolescents, and young adults (AYAs) with pediatric cancers. However, challenges in sharing data between institutions, particularly in...
3.
Ligon J, Sundby R, Wedekind M, Arnaldez F, Del Rivero J, Wiener L, et al.
Clin Cancer Res
. 2022 Oct;
29(2):341-348.
PMID: 36302175
Purpose: Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) without KIT or platelet-derived growth factor receptor alpha...
4.
Meltzer P, Helman L
N Engl J Med
. 2021 Nov;
385(22):2066-2076.
PMID: 34818481
No abstract available.
5.
McEachron T, Helman L
Cancer Res
. 2021 Sep;
81(23):5783-5799.
PMID: 34561271
Over the past few years, the field of pediatric cancer has experienced a shift in momentum, and this has led to new and exciting findings that have relevance beyond pediatric...
6.
Chugh R, Ballman K, Helman L, Patel S, Whelan J, Widemann B, et al.
Cancer
. 2020 Dec;
127(8):1301-1310.
PMID: 33289920
Background: In preclinical Ewing sarcoma (ES) models, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with synergy in combination with cytotoxic agents. This study evaluated...
7.
Slemmons K, Mukherjee S, Meltzer P, Purcell J, Helman L
Pediatr Blood Cancer
. 2020 Oct;
68(2):e28771.
PMID: 33063919
Background: Osteosarcoma (OS), the most common bone tumor in children and adolescents, has high rates of metastasis leading to poor survival. Leucine-rich repeat containing 15 (LRRC15), a transmembrane protein whose...
8.
Darvishi E, Slemmons K, Wan Z, Mitra S, Hou X, Parmentier J, et al.
Neoplasia
. 2020 May;
22(7):274-282.
PMID: 32464274
Fibroblast growth factor receptor 4 (FGFR4) aberrant expression and activity have been linked to the pathogenesis of a variety of cancers including rhabdomyosarcomas (RMS). We found that treatment of alveolar...
9.
Issaq S, Mendoza A, Kidner R, Rosales T, Duveau D, Heske C, et al.
Mol Cancer Ther
. 2020 May;
19(7):1520-1529.
PMID: 32371575
Despite a growing body of knowledge about the genomic landscape of Ewing sarcoma, translation of basic discoveries into targeted therapies and significant clinical gains has remained elusive. Recent insights have...
10.
Slemmons K, Yeung C, Baumgart J, Juarez J, McCalla A, Helman L
Cancer Res
. 2020 May;
80(14):3046-3056.
PMID: 32354737
Rhabdomyosarcoma is the most common childhood soft-tissue sarcoma, yet patients with metastatic or recurrent disease continue to do poorly, indicating a need for new treatments. The SRC family tyrosine kinase...